SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

3235-0104 OMB Number:

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

		or Se	ection :	30(h) of	the Investment Company	ACT C	of 1940					
1. Name and Address of Reporting Person [*] Atlas Venture Fund XI, L.P.		Requirin (Month/E	2. Date of Event Requiring Statement (Month/Day/Year) 09/16/2020		3. Issuer Name and Ticker or Trading Symbol <u>Dyne Therapeutics, Inc.</u> [DYN]							
(Last) (First) (Middle) 400 TECHNOLOGY SQUARE,					4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owne Officer (give Other (spec title below) below)				5. If Amendment, Date of Original Filed (Month/Day/Year)			
10TH FLOOR										 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person 		
(Street) CAMBRIDGE MA 02139									x			
(City) (State)) (Zip)					C						
		Table I - No	on-D	eriva	tive Securities Bene	TIC	ially Ov	vnea				
1. Title of Security (In				Beneficially Owned (Instr. Form: I 4) (D) or I		3. Owne Form: D (D) or In (I) (Instr.	oirect Owne direct		ature of Indirect Beneficial hership (Instr. 5)			
Common Stock				2,110,404		I		See footnote ⁽¹⁾				
	(e				e Securities Benefic ants, options, conve)			
1. Title of Derivative Security (Instr. 4)		Expiration D	2. Date Exercisable and Expiration Date Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of		5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr.		
		Date Exercisable			Title	Amount or Number of Shares		Derivative Security		or Indirect (I) (Instr. 5)	5)	
Series A Preferred Stock		(2)	((2)	Common Stock	6,0	029,726	(2	!)	Ι	See footnote ⁽¹⁾	
Series B Preferred Stock		(3)	((3)	Common Stock	1,0	608,785	(3	i)	Ι	See footnote ⁽⁴⁾	
1. Name and Address <u>Atlas Venture I</u>		•										
(Last) (400 TECHNOLOG	, , , ,	Middle) TH FLOOR										
(Street) CAMBRIDGE	MA (02139										
(City) (State) (Zip)										
1. Name and Address <u>Atlas Venture A</u>												
(Last) (400 TECHNOLOG		Middle) TH FLOOR										
(Street) CAMBRIDGE	MA (02139										
(City) (State) (Zip)										
1. Name and Address	of Reporting Person	ĸ										

Atlas Venture Associates XI, L.P.							
(Last) 400 TECHNOL	(First) OGY SQUARE,	(Middle) 10TH FLOOR					
(Street) CAMBRIDGE	МА	02139					
(City)	(State)	(Zip)					
	ss of Reporting Pers <u>e Opportunity</u>						
	(First) OGY SQUARE,	(Middle) 10TH FLOOR					
(Street) CAMBRIDGE	МА	02139					
(City)	(State)	(Zip)					
	ss of Reporting Pers <u>Associates O</u>						
(Last) 400 TECHNOL	(First) OGY SQUARE,	(Middle) 10TH FLOOR					
(Street) CAMBRIDGE	МА	02139					
(City)	(State)	(Zip)					
	ss of Reporting Pers Associates O						
(Last) 400 TECHNOL	(First) OGY SQUARE,	(Middle) 10TH FLOOR					
(Street) CAMBRIDGE	МА	02139					
(City)	(State)	(Zip)					

Explanation of Responses:

1. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.

2. The Series A Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

3. The Series B Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

4. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.

Remarks:

/s/ Atlas Venture Fund XI, 09/16/2020 LP, By: Atlas Venture Associates XI, L.P., it's general partner, By: Atlas Venture Associates XI, LLC, its general partner, By: Ommer Chohan, Chief

<u>Financial Officer, /s/</u> Ommer Chohan	
/s/ Atlas Venture Associates XI, LP, By: Atlas Venture Associates XI, LLC, it's general partner, By: Ommer Chohan, Chief Financial Officer, /s/ Ommer Chohan	<u>09/16/2020</u>
<u>/s/ Atlas Venture</u> <u>Associates XI, LLC, By:</u> <u>Ommer Chohan, Chief</u> <u>Financial Officer, /s/</u> <u>Ommer Chohan</u>	<u>09/16/2020</u>
<u>/s/ Atlas Venture</u> <u>Opportunity Fund I, L.P.,</u> <u>By: Atlas Venture</u> <u>Associates Opportunity I,</u> <u>L.P., its general partner,</u> <u>By: Atlas Venture</u> <u>Associates Opportunity I,</u> <u>LLC, its general partner,</u> <u>By: Ommer Chohan, Chief</u> <u>Financial Officer, /s/</u> <u>Ommer Chohan</u>	<u>09/16/2020</u>
<u>/s/ Atlas Venture</u> <u>Associates Opportunity I,</u> <u>L.P., By: Atlas Venture</u> <u>Associates Opportunity I,</u> <u>LLC, its general partner,</u> <u>By: Ommer Chohan, Chief</u> <u>Financial Officer, /s/</u> <u>Ommer Chohan</u>	<u>09/16/2020</u>
<u>/s/ Atlas Venture</u> <u>Associates Opportunity I</u> , <u>LLC, By: Ommer Chohan,</u> <u>Chief Financial Officer, /s/</u> <u>Ommer Chohan</u> ** Signature of Reporting	<u>09/16/2020</u> Date
Person	Dale

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.